Back to top
more

Enanta Pharmaceuticals (ENTA)

(Delayed Data from NSDQ)

$12.37 USD

12.37
67,161

-0.11 (-0.88%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $12.38 +0.01 (0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4

Endo International (ENDP)'s fourth quarter results surpassed expectations but were down year-over-year due to weakness in the generics business.

    Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y

    Jazz Pharmaceuticals (JAZZ) earnings and revenues miss estimates in Q4. However, the company posts a strong bottom and top-line guidance for 2018.

      AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues

      AMAG Pharma (AMAG) beats earnings and misses sales estimates in the fourth quarter of 2017.

        Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down

        Perrigo (PRGO) to reschedule fourth-quarter 2017 and full-year earnings results. However, the company releases preliminary unaudited numbers for the full year.

          Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4

          Endocyte, Inc. (ECYT) posts wider-than-expected loss in the fourth quarter of 2017. The company finalized a phase III VISION trial design for 177Lu-PSMA-617 following a successful End of Phase II meeting with the FDA.

            Corcept's (CORT) Earnings and Sales Meet Estimates in Q4

            Corcept (CORT) reports in-line results for the fourth quarter of 2017 and also announces top-line interim phase II data for its pipeline candidate relacorilant.

              AbbVie Presents New Data on Upadacitinib for Crohn's Disease

              AbbVie (ABBV) announces new data from a phase II study on upadacitinib in adult patients with moderately to severely active Crohn's disease.

                Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View

                Zoetis' (ZTS) results exceed both earnings and sales expectations in the fourth quarter of 2017, making it the first animal health company to deliver more than $5 billion in revenues.

                  Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong

                  Shire (SHPG) reported better-than-expected fourth-quarter earnings and also registered strong growth in immunology franchise and newly launched products.

                    AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda

                    AVEO Oncology (AVEO) is due to receive $2 million from its partner EUSA Pharma as the latter has been granted positive NICE recommendation for Fotivda (tivozanib).

                      Will Conatus Liver Disease Candidate Drive Long-Term Growth?

                      Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.

                        Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 9.6% in Session

                        Enanta Pharmaceuticals, Inc. (ENTA) was a big mover last session, as the company saw its shares rise over 9% on the day.

                          Surging Earnings Estimates Signal Good News for Enanta Pharmaceuticals (ENTA)

                          Enanta Pharmaceuticals (ENTA) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.

                            Will Conatus Key Candidate Emricasan Drive Long-Term Growth?

                            Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.

                              AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada

                              AbbVie (ABBV) announces Mavyret's sanction in Canada for treatment of HCV across all major genotypes. This gain serves a big boost to the company's product portfolio.

                                Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment

                                Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment

                                  Buy These 5 Stocks on New Analyst Coverage

                                  Increased analyst coverage over the last few weeks might translate into solid price appreciation for these stocks.

                                    Arpita Dutt headshot

                                    4 Drug Stocks in Focus this World Hepatitis Day

                                    Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

                                      AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU

                                      AbbVie Inc. (ABBV) announced that the CHMP of the EMA has recommended marketing approval of its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).

                                        AbbVie (ABBV) Presents Positive Data on HCV Combination Drug

                                        AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)

                                          AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada

                                          AbbVie Inc. (ABBV) announced that its New Drug Submission (NDS) for an investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) received priority review in Canada for treatment of HCV.

                                            AbbVie's HCV Regimen Okayed for Accelerated Assessment

                                            AbbVie Inc. (ABBV) recently announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application for its investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P).